CCM
PACB icon

Consonance Capital Management’s Pacific Biosciences PACB Stock Holding History

Consonance Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,455,114
Closed -$18.2M – 29
2018
Q4 		$18.2M Sell
2,455,114
-11,057,844
-82% -$70.1M 1.34% 17
2018
Q3 		$73.1M Buy
13,512,958
+936,956
+7% +$4.02M 3.94% 12
2018
Q2 		$44.6M Hold
12,576,002
– – 2.88% 15
2018
Q1 		$25.8M Buy
12,576,002
+5,510,082
+78% +$14.3M 2.36% 17
2017
Q4 		$18.7M Buy
7,065,920
+164,492
+2% +$576K 1.68% 15
2017
Q3 		$36.2M Buy
6,901,428
+3,068,715
+80% +$13.2M 4.01% 12
2017
Q2 		$13.6M Buy
+3,832,713
New +$15.5M 1.61% 14
2016
Q3 		– Sell
-1,114,448
Closed -$7.84M – 26
2016
Q2 		$7.84M Sell
1,114,448
-3,403,069
-75% -$31.1M 1.11% 16
2016
Q1 		$38.4M Sell
4,517,517
-981,195
-18% -$9.65M 5.81% 8
2015
Q4 		$72.2M Sell
5,498,712
-759,149
-12% -$6.81M 9.68% 4
2015
Q3 		$22.9M Buy
6,257,861
+859,000
+16% +$4.2M 3.22% 10
2015
Q2 		$31.1M Buy
5,398,861
+3,395,890
+170% +$19.6M 3.12% 11
2015
Q1 		$11.7M Buy
+2,002,971
New +$13.8M 1.07% 20

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Consonance Capital Management's PACB Position: Q1 2019 in Review

Consonance Capital Management sold out of Pacific Biosciences (PACB) in Q1 2019, closing a stake of 2,455,114 shares — an estimated $18.2M sold.

Consonance Capital Management first reported a position in PACB in Q1 2015 and held it in 13 quarters. The position peaked at $73.1M in Q3 2018. 160 funds tracked by Wall St. Rank hold PACB as of Q1 2019.

  • Consonance Capital Management reported no remaining Pacific Biosciences position as of Q1 2019 after selling out during the quarter.
  • Consonance Capital Management sold 2,455,114 Pacific Biosciences shares in Q1 2019, an estimated $18.2M.
  • Consonance Capital Management first reported a position in Pacific Biosciences in Q1 2015 and held it in 13 quarters.
  • Consonance Capital Management's Pacific Biosciences position peaked at $73.1M in Q3 2018.
  • 160 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2019.

Based on Consonance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.